Clinical Trial Update: Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating a pharmacokinetic boosting strategy for olaparib to improve exposure and tolerability, with a focus on cost-effectiveness…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Cancer | Phase 4 | Status: RECRUITING